1. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1213,
1999,
Page 2-2
&NA;,
Preview
|
PDF (788KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
2. |
Bisphosphonates revolutionise the treatment of Paget's disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1213,
1999,
Page 3-4
Robert Carlson,
Preview
|
PDF (1628KB)
|
|
摘要:
The advent of the new bisphosphonates means that the era of observing the natural history of untreated Paget's disease is over, said Dr Henry Bone from Michigan Bone and Mineral Clinic, Detroit, Michigan, US, speaking at the 21st annual meeting of the American Society for Bone and Mineral Research [St. Louis, US; October 1999]. This is because bisphosphonates are very effective in stopping the progression of Paget's disease.
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
3. |
AAP issues guidelines on thiomersal in vaccines |
|
Inpharma Weekly,
Volume &NA;,
Issue 1213,
1999,
Page 4-4
&NA;,
Preview
|
PDF (832KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
4. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1213,
1999,
Page 5-5
&NA;,
Preview
|
PDF (752KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
5. |
Palivizumab for RSV prophylaxis cost effective for high-risk infants |
|
Inpharma Weekly,
Volume &NA;,
Issue 1213,
1999,
Page 6-7
&NA;,
Preview
|
PDF (1529KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
6. |
High-dose oxytocin shortens labour and is cost saving |
|
Inpharma Weekly,
Volume &NA;,
Issue 1213,
1999,
Page 7-7
&NA;,
Preview
|
PDF (784KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
7. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1213,
1999,
Page 8-8
&NA;,
Preview
|
PDF (784KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
8. |
New cefalosporin shows promise against respiratory infections |
|
Inpharma Weekly,
Volume &NA;,
Issue 1213,
1999,
Page 9-10
Larry Prescott,
Preview
|
PDF (1576KB)
|
|
摘要:
Cefditoren pivoxil [cefditoren; ‘Spectracef’], a new investigational oral cefalosporin with broad spectrum activity against both Gram-positive and Gram-negative bacteria, appears to be effective and well tolerated in the treatment of streptococcal pharyngitis and acute bacterial exacerbations of chronic bronchitis (AECB). Data from 2 phase III clinical trials andin vitroantimicrobial activity studies demonstrating these findings were presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy [San Francisco, US; September 1999].*
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
9. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1213,
1999,
Page 10-10
&NA;,
Preview
|
PDF (792KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
10. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1213,
1999,
Page 11-11
&NA;,
Preview
|
PDF (733KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|